Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist

PHASE4TerminatedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Type 2 Diabetes MellitusBone Remodeling
Interventions
DRUG

exenatide

exenatide 5mcg sq twice daily for one month and exenatide 10mcg twice daily for month 2. The 3rd month is a washout period. Month 4 and 5 saline placebo is given as 5mcg and 10mcg respectively.

DRUG

Saline

Month 1 and 2 saline placebo is given as a low and high dose respectively. The 3rd month is a washout period. Month 4 exenatide 5mcg sq twice daily and for month 5 exenatide 10mcg twice daily is administered.

Trial Locations (1)

35294

University of Alabama at Birmingham, Birmingham

Sponsors
All Listed Sponsors
collaborator

Amylin Pharmaceuticals, LLC.

INDUSTRY

lead

University of Alabama at Birmingham

OTHER